Sign inJoin waitlistJoin the waitlist

Fauzia Riaz

Assistant Professor, Medicine – Oncology · Stanford Health Care

Credentials: · · · · · ·

History

Yale Cancer Center (2019) CT
2017–2019
MedStar Georgetown University Hospital
2013–2016
USF Health Morsani College of Medicine
2008–2012

Research

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Journal of the National Comprehensive Cancer Network · 2022 · 70 citations
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers
JAMA Oncology · 2021 · 53 citations
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice
The Oncologist · 2019 · 40 citations

Cary Gross
4 papers
Jennifer Caswell-Jin
4 papers
Ravi Parikh
4 papers · 3 as a fellow
Amor Khachemoune
3 papers
James Dickerson
3 papers
Ronac Mamtani
3 papers
Carolyn Presley
2 papers
Kerin Adelson
2 papers
Melinda Telli
2 papers
RC
Roger Cohen
2 papers
Ali Khaki
1 paper
Allison Kurian
1 paper

Clinical trials

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Site PI · Recruiting · Phase 3
Greenwich LifeSciences, Inc.
2022–2031